遺伝子パネルの世界市場 - 産業規模、シェア、動向、機会、予測、コンポーネント別、技術別、エンドユーザー別、地域別、競合（2020年～2030年）

世界の遺伝子パネルの市場規模は2024年に29億8,000万米ドルで、予測期間中のCAGRは7.45%で2030年には45億5,000万米ドルに達すると予測されています。

世界の遺伝子パネル市場は、様々な疾患の早期診断・治療における遺伝子検査の重要性の高まりに牽引され、堅調な拡大を見せています。複数の遺伝子を同時に解析できる遺伝子パネルは、腫瘍学、希少疾患検出、薬理ゲノミクスの分野で要となっています。個別化医療や標的治療へのシフトは、特に遺伝性がんリスク評価、先天性疾患、神経疾患に対する遺伝子パネル検査の採用を大きく後押ししています。次世代シーケンシング（NGS）の技術的進歩は、遺伝子バリアントの解析をより迅速、正確、かつコスト効率よく行うことを可能にし、この成長において極めて重要です。アンプリコンベースやハイブリッドキャプチャーベースの技術により、研究者や臨床医は特定の臨床要件に応じて遺伝子パネルをカスタマイズすることが容易になりました。例えば、2023年10月、中国の国家医薬品監督管理局（NMPA）は、非小細胞肺がん（NSCLC）に対するGeneseeqの腫瘍変異負荷検査キットを承認しました。このキットは425のがん関連遺伝子を網羅する包括的な遺伝子パネルを特徴としており、肺がん患者のより正確な診断と治療計画をサポートすることで精密腫瘍学を強化することを目指しています。

シークエンシング技術の低価格化と患者・医療従事者の意識の高まりにより、先進国・新興国を問わず遺伝子パネルの市場浸透が加速しています。世界中のヘルスケアシステムは、特にがん診断のために、遺伝子情報を臨床ワークフローに組み込むようになってきています。乳がん、大腸がん、卵巣がんなどでは、治療方針の決定に多遺伝子パネルが頻繁に使用されるようになっています。遺伝子パネルは、がん領域以外にも、循環器領域、感染症領域、出生前検査領域でも普及しつつあり、その応用範囲は広がっています。

主要市場促進要因

遺伝性疾患および慢性疾患の発症率の上昇

主要市場課題

検査と機器の高コスト

主要市場動向

人工知能と機械学習の統合

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の遺伝子パネル市場の展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • コンポーネント別（テストキット、テストサービス）
  • 技術別（アンプリコンベースのアプローチ、ハイブリダイゼーションベースのアプローチ）
  • エンドユーザー別（学術・研究機関、病院・診断研究所、製薬・バイオテクノロジー企業）
  • 地域別
  • 企業別（2024年）
• 市場マップ

第6章 北米の遺伝子パネル市場の展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第7章 欧州の遺伝子パネル市場の展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • 英国
  • イタリア
  • スペイン

第8章 アジア太平洋の遺伝子パネル市場の展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋：国別分析
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア

第9章 南米の遺伝子パネル市場の展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの遺伝子パネル市場の展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 合併と買収
• 製品上市

第13章 競合情勢

• Illumina, Inc.
• Agilent Technologies, Inc.
• Thermo Fischer Scientific, Inc.
• QIAGEN NV
• Eurofins Scientific SE
• Foundation Medicine Inc.
• Guardant Health, Inc.
• Myriad Genetic Laboratories Inc.
• Bio-Rad Laboratories, Inc.
• F. Hoffmann-La Roche AG

第14章 戦略的提言

第15章 調査会社について・免責事項

Global Gene Panel Market was valued at USD 2.98 billion in 2024 and is expected to reach USD 4.55 billion by 2030 with a CAGR of 7.45% during the forecast period. The global gene panel market is witnessing robust expansion, driven by the growing importance of genetic testing in the early diagnosis and treatment of various diseases. Gene panels, which allow simultaneous analysis of multiple genes, have become a cornerstone in the fields of oncology, rare disease detection, and pharmacogenomics. The shift toward personalized medicine and targeted therapies has significantly boosted the adoption of gene panel testing, especially for hereditary cancer risk assessment, congenital disorders, and neurological diseases. Technological advancements in next-generation sequencing (NGS) have been pivotal in this growth, enabling faster, more accurate, and cost-effective analysis of gene variants. Amplicon-based and hybrid-capture based techniques have made it easier for researchers and clinicians to customize gene panels according to specific clinical requirements. For instance, in October 2023, China's National Medical Products Administration (NMPA) approved Geneseeq's tumor mutational burden test kit for non-small cell lung cancer (NSCLC). The kit features a comprehensive gene panel covering 425 cancer-related genes, aiming to enhance precision oncology by supporting more accurate diagnosis and treatment planning in lung cancer patients.

The decreasing cost of sequencing technologies and growing awareness among patients and healthcare providers are accelerating the market penetration of gene panels across both developed and emerging economies. Healthcare systems around the world are increasingly incorporating genetic information into clinical workflows, particularly for cancer diagnostics. Multigene panels are now frequently used to guide treatment decisions in breast, colorectal, and ovarian cancers. Beyond oncology, gene panels are also gaining traction in cardiology, infectious diseases, and prenatal testing, widening their scope of applications.

Key Market Drivers

Rising Incidence of Genetic and Chronic Diseases

The rising incidence of genetic and chronic diseases is a major driver propelling the growth of the global gene panel market. For instance, according to the Genetic and Rare Disease (GARD) Information Center, over 7,000 genetic conditions have been identified, with the number steadily increasing. In the U.S., at least 200,000 individuals live with known genetic disorders, while in the U.K., around 30,000 infants are diagnosed annually, contributing to over 2.4 million survivors. Gene panels are often developed to detect such conditions at birth, enabling timely diagnosis and early intervention through appropriate treatment and management strategies. This early detection plays a crucial role in improving patient outcomes and reducing the long-term burden of genetic diseases. Over the past decade, there has been a significant increase in the prevalence of genetic disorders such as cystic fibrosis, thalassemia, and sickle cell anemia, as well as complex chronic conditions like cancer, cardiovascular diseases, and neurodegenerative disorders. Many of these diseases have a strong genetic component, making early and accurate detection through gene panels a critical aspect of modern diagnostics. Gene panels allow clinicians to analyze multiple genes simultaneously to identify mutations associated with hereditary conditions, enabling timely intervention and better disease management. Cancer, in particular, has seen an alarming rise worldwide, with a growing emphasis on personalized treatment approaches based on individual genetic profiles. Gene panel testing has become an essential tool in oncology, helping to detect germline and somatic mutations that influence cancer susceptibility and treatment response. For instance, BRCA1 and BRCA2 gene panels are widely used to assess the risk of breast and ovarian cancers, guiding both preventive strategies and therapeutic choices. Similarly, chronic illnesses such as diabetes, Alzheimer's disease, and cardiovascular disorders often have underlying genetic factors that can be identified through targeted panels, allowing for more precise risk stratification and personalized care plans.

Key Market Challenges

High Cost of Testing and Equipment

The high cost of advanced filtration systems presents a significant challenge to the global gene panel market. As laboratories increasingly demand high-performance solutions for applications in pharmaceuticals, biotechnology, environmental testing, and academic research, the complexity and technological sophistication of filtration equipment have grown. However, this advancement comes at a cost-systems such as nanofiltration, ultrafiltration, and automated filtration setups require substantial capital investment. For many small- to medium-sized laboratories, especially in developing regions, these costs can be prohibitive. Beyond initial acquisition, ongoing operational expenses further burden end users. Advanced filtration systems often require specialized membranes, maintenance kits, calibration, and sometimes custom configurations to suit specific applications. The need for compatibility with other lab infrastructure or integration into automated workflows can increase the total cost of ownership. In sectors where funding is limited or subject to fluctuations, such as academic or public health labs, high-cost systems may be considered an unjustifiable expenditure, leading to reliance on outdated or less efficient alternatives.

Key Market Trends

Integration of Artificial Intelligence and Machine Learning

The integration of Artificial Intelligence (AI) and Machine Learning (ML) into the global gene panel market is rapidly transforming the landscape of genetic testing and precision medicine. AI and ML technologies enhance the ability to analyze vast amounts of genomic data quickly and accurately, addressing one of the key challenges in gene panel testing-interpreting complex genetic variations and identifying clinically relevant mutations. By leveraging sophisticated algorithms, AI can detect subtle patterns and correlations within genetic datasets that may be missed by traditional methods, leading to improved diagnostic accuracy and personalized treatment recommendations.

In gene panel testing, AI-driven tools are increasingly used for variant classification, predicting pathogenicity, and prioritizing genetic mutations for clinical relevance. Machine learning models trained on large genomic databases help in distinguishing benign variants from those linked to disease, reducing the number of variants of unknown significance (VUS) and enhancing the clinical utility of gene panels. This capability is particularly valuable in oncology, where identifying actionable mutations can guide targeted therapies and immunotherapies, improving patient outcomes. AI and ML enable automation of data processing pipelines, decreasing turnaround times and operational costs, which makes gene panel testing more accessible and scalable. The combination of AI with next-generation sequencing (NGS) platforms has led to the development of comprehensive cancer profiling assays that integrate genomic and epigenomic data, providing a more holistic view of tumor biology. For example, companies like Guardant Health use AI-powered liquid biopsy tests that non-invasively profile cancer-related genetic changes from blood samples, demonstrating the potential for less invasive and more frequent monitoring.

Key Market Players

• Illumina, Inc.
• Agilent Technologies, Inc.
• Thermo Fischer Scientific, Inc.
• QIAGEN NV
• Eurofins Scientific SE
• Foundation Medicine Inc.
• Guardant Health, Inc.
• Myriad Genetic Laboratories Inc.
• Bio-Rad Laboratories, Inc.
• F. Hoffmann-La Roche AG

Report Scope:

In this report, the Global Gene Panel Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Gene Panel Market, By Component:

• Test Kits
• Testing Services

Gene Panel Market, By Technique:

• Amplicon Based Approach
• Hybridization Based Approach

Gene Panel Market, By End User:

• Academic & Research Institute
• Hospital & Diagnostic Laboratories
• Pharmaceutical & Biotechnology Companies

Gene Panel Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Gene Panel Market.

Available Customizations:

Global Gene Panel Market report with the given Market data, TechSci Research, offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional Market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Gene Panel Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Component (Test Kits v/s Testing Services)
  • 5.2.2. By Technique (Amplicon Based Approach v/s Hybridization Based Approach)
  • 5.2.3. By End User (Academic & Research Institutes, Hospital & Diagnostic Laboratories, Pharmaceutical & Biotechnology Companies)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. North America Gene Panel Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Component
  • 6.2.2. By Technique
  • 6.2.5. By End User
  • 6.2.6. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Gene Panel Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Component
      • 6.3.1.2.2. By Technique
      • 6.3.1.2.5. By End User
  • 6.3.2. Canada Gene Panel Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Component
      • 6.3.2.2.2. By Technique
      • 6.3.2.2.5. By End User
  • 6.3.3. Mexico Gene Panel Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Component
      • 6.3.3.2.2. By Technique
      • 6.3.3.2.5. By End User

7. Europe Gene Panel Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Component
  • 7.2.2. By Technique
  • 7.2.5. By End User
  • 7.2.6. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Gene Panel Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Component
      • 7.3.1.2.2. By Technique
      • 7.3.1.2.5. By End User
  • 7.3.2. Germany Gene Panel Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Component
      • 7.3.2.2.2. By Technique
      • 7.3.2.2.5. By End User
  • 7.3.3. United Kingdom Gene Panel Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Component
      • 7.3.3.2.2. By Technique
      • 7.3.3.2.5. By End User
  • 7.3.4. Italy Gene Panel Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Component
      • 7.3.4.2.2. By Technique
      • 7.3.4.2.5. By End User
  • 7.3.5. Spain Gene Panel Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Component
      • 7.3.5.2.2. By Technique
      • 7.3.5.2.5. By End User

8. Asia-Pacific Gene Panel Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Component
  • 8.2.2. By Technique
  • 8.2.5. By End User
  • 8.2.6. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Gene Panel Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Component
      • 8.3.1.2.2. By Technique
      • 8.3.1.2.5. By End User
  • 8.3.2. India Gene Panel Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Component
      • 8.3.2.2.2. By Technique
      • 8.3.2.2.5. By End User
  • 8.3.3. Japan Gene Panel Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Component
      • 8.3.3.2.2. By Technique
      • 8.3.3.2.5. By End User
  • 8.3.4. South Korea Gene Panel Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Component
      • 8.3.4.2.2. By Technique
      • 8.3.4.2.5. By End User
  • 8.3.5. Australia Gene Panel Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Component
      • 8.3.5.2.2. By Technique
      • 8.3.5.2.5. By End User

9. South America Gene Panel Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Component
  • 9.2.2. By Technique
  • 9.2.5. By End User
  • 9.2.6. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Gene Panel Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Component
      • 9.3.1.2.2. By Technique
      • 9.3.1.2.5. By End User
  • 9.3.2. Argentina Gene Panel Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Component
      • 9.3.2.2.2. By Technique
      • 9.3.2.2.5. By End User
  • 9.3.3. Colombia Gene Panel Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Component
      • 9.3.3.2.2. By Technique
      • 9.3.3.2.5. By End User

10. Middle East and Africa Gene Panel Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Component
  • 10.2.2. By Technique
  • 10.2.5. By End User
  • 10.2.6. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Gene Panel Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Component
      • 10.3.1.2.2. By Technique
      • 10.3.1.2.5. By End User
  • 10.3.2. Saudi Arabia Gene Panel Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Component
      • 10.3.2.2.2. By Technique
      • 10.3.2.2.5. By End User
  • 10.3.3. UAE Gene Panel Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Component
      • 10.3.3.2.2. By Technique
      • 10.3.3.2.5. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Competitive Landscape

• 13.1. Illumina, Inc.
  • 13.1.1. Business Overview
  • 13.1.2. Product Offerings
  • 13.1.3. Recent Developments
  • 13.1.4. Financials (As Reported)
  • 13.1.5. Key Personnel
  • 13.1.6. SWOT Analysis
• 13.2. Agilent Technologies, Inc.
• 13.3. Thermo Fischer Scientific, Inc.
• 13.4. QIAGEN NV
• 13.5. Eurofins Scientific SE
• 13.6. Foundation Medicine Inc.
• 13.7. Guardant Health, Inc.
• 13.8. Myriad Genetic Laboratories Inc.
• 13.9. Bio-Rad Laboratories, Inc.
• 13.10. F. Hoffmann-La Roche AG

14. Strategic Recommendations

15. About Us & Disclaimer